MLTX Earnings & Financial Statements
MoonLake Immunotherapeutics
$10.58
-$0.19(-1.76%)
40
Overall
60
Value
36
Tech
26
Quality
Market Cap
$916.60M
Volume
3.72M
52W Range
$8.18 - $23.29
Target Price
$33.46
MLTX earnings and financial statements: MoonLake Immunotherapeutics's income statement, balance sheet and cash flow statement, annual and quarterly.
MLTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | -$2.30M |
| Operating income | -$244.83M | -$143.09M | -$54.12M | -$65.06M | -$4.57M |
| EBITDA | -$219.85M | -$119.58M | -$43.58M | -$64.46M | -$4.57M |
| Net income | -$227.32M | -$118.94M | -$36.01M | -$49.97M | -$4.54M |
| EPS (diluted) | $-3.53 | $-1.89 | $-0.73 | $-1.70 | $-0.31 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $424.43M | $477.93M | $526.54M | $76.84M | $9.68M |
| Total liabilities | $119.95M | $24.54M | $13.05M | $8.08M | $21.33M |
| Shareholders’ equity | $304.48M | $446.82M | $495.68M | $48.90M | -$11.65M |
| Cash and equivalents | $334.52M | $180.43M | $451.17M | $39.51M | $8.04M |
| Long-term debt | $74.47M | $1.46M | $2.50M | $129.0K | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$196.01M | -$116.59M | -$42.78M | -$55.89M | -$611.1K |
| Capital expenditure | -$35.0K | -$520.0K | -$284.6K | -$16.0K | - |
| Free cash flow | -$196.04M | -$117.11M | -$43.06M | -$55.91M | -$611.1K |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MLTX | $10.58 | -1.8% | 3.72M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get MoonLake Immunotherapeutics Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW